Country: United States
Language: English
Source: NLM (National Library of Medicine)
cisplatin (UNII: Q20Q21Q62J) (cisplatin - UNII:Q20Q21Q62J)
Corden Pharma Latina S.p.A.
cisplatin
cisplatin 1 mg in 1 mL
INTRAVENOUS
PRESCRIPTION DRUG
PLATINOL-AQ (cisplatin injection) is indicated as therapy to be employed as follows: In established combination therapy with other approved chemotherapeutic agents in patients with metastatic testicular tumors who have already received appropriate surgical and/or radiotherapeutic procedures. In established combination therapy with other approved chemotherapeutic agents in patients with metastatic ovarian tumors who have already received appropriate surgical and/or radiotherapeutic procedures. An established combination consists of PLATINOL-AQ and cyclophosphamide. PLATINOL-AQ, as a single agent, is indicated as secondary therapy in patients with metastatic ovarian tumors refractory to standard chemotherapy who have not previously received PLATINOL-AQ therapy. PLATINOL-AQ is indicated as a single agent for patients with transitional cell bladder cancer which is no longer amenable to local treatments, such as surgery and/or radiotherapy. PLATINOL-AQ is contraindicated in patients with preexisting renal impairme
PLATINOL® -AQ (cisplatin injection) NDC 61126-004-01—Each multidose vial contains 50 mg of cisplatin NDC 61126-004-02—Each multidose vial contains 100 mg of cisplatin
New Drug Application
PLATINOL-AQ- CISPLATIN INJECTION, SOLUTION CORDEN PHARMA LATINA S.P.A. ---------- PLATINOL -AQ (CISPLATIN INJECTION) RX ONLY WARNING PLATINOL-AQ (cisplatin injection) should be administered under the supervision of a qualified physician experienced in the use of cancer chemotherapeutic agents. Appropriate management of therapy and complications is possible only when adequate diagnostic and treatment facilities are readily available. Cumulative renal toxicity associated with PLATINOL-AQ is severe. Other major dose-related toxicities are myelosuppression, nausea, and vomiting. Ototoxicity, which may be more pronounced in children, and is manifested by tinnitus, and/or loss of high frequency hearing and occasionally deafness, is significant. _Anaphylactic-like_ reactions to PLATINOL-AQ have been reported. Facial edema, bronchoconstriction, tachycardia, and hypotension may occur within minutes of PLATINOL-AQ administration. Epinephrine, corticosteroids, and antihistamines have been effectively employed to alleviate symptoms (see WARNINGS and ADVERSE REACTIONS sections). EXERCISE CAUTION TO PREVENT INADVERTENT PLATINOL-AQ OVERDOSE. Doses greater than 100 mg/m /cycle once every 3 to 4 weeks are rarely used. Care must be taken to avoid inadvertent PLATINOL-AQ overdose due to confusion with PARAPLATIN (carboplatin) or prescribing practices that fail to differentiate daily doses from total dose per cycle. DESCRIPTION PLATINOL -AQ (cisplatin injection) infusion concentrate is a clear, colorless, sterile aqueous solution available in amber vials. Each 50 mL or 100 mL amber vial of infusion concentrate contains: 1 mg/mL cisplatin, 9 mg/mL sodium chloride, hydrochloric acid and sodium hydroxide to approximate pH of 4.0, and water for injection to a final volume of 50 mL or 100 mL, respectively. PLATINOL -AQ (cisplatin injection) infusion concentrate must be further diluted prior to administration (see DOSAGE AND ADMINISTRATION: ALL PATIENTS). The active ingredient, cisplatin, is a yellow to orange crystalline powder with the Read the complete document